Rational humanization of the powerful antithrombotic anti-GPIbα antibody: 6B4

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Thrombosis and Haemostasis

• Publication date

  2006-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1160/TH06-06-0297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.

  2006influential reference
• Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice

  2004influential reference
• Function‐modulating human monoclonal antibodies against platelet‐membrane receptors isolated from a phage‐display library

  2003cited by this paper
• Fast and accurate side‐chain topology and energy refinement (FASTER) as a new method for protein structure optimization

  2002cited by this paper
• [Construction and characterization of bispecific single-chain antibody fragments SZ-2/SZ-21 against platelet glycoprotein Ib alpha and beta3].

  2002cited by this paper
• Crystal Structure of the Platelet Glycoprotein Ibα N-terminal Domain Reveals an Unmasking Mechanism for Receptor Activation*

  2002cited by this paper
• Inhibition of Platelet Glycoprotein Ib, Glycoprotein IIb/IIIa, or Both by Monoclonal Antibodies Prevents Arterial Thrombosis in Baboons

  2002influential reference
• Structures of Glycoprotein Ibα and Its Complex with von Willebrand Factor A1 Domain

  2002influential reference
• Generation and Characterization of Recombinant ScFv Antibodies Detecting Eimeria acervulina Surface Antigens

  2001cited by this paper
• Fc-receptor Dependent Platelet Aggregation Induced by Monoclonal Antibodies against Platelet Glycoprotein Ib or von Willebrand Factor

  2001cited by this paper
• Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha.

  2001cited by this paper
• A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

  2000influential reference
• Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

  2000influential reference
• Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity.

  2000cited by this paper
• Humanization of an antibody against human protein C and calcium-dependence involving framework residues.

  1998cited by this paper
• Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

  1997cited by this paper
• A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.

  1996cited by this paper
• Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.

  1996cited by this paper
• The mechanism of cold-induced platelet aggregation in the presence of heparin.

  1995cited by this paper
• Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions.

  1995cited by this paper
• Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates.

  1994cited by this paper
• Humanization of murine monoclonal antibodies through variable domain resurfacing.

  1994cited by this paper
• Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers.

  1994cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.

  1991cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper
• Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

  1989cited by this paper
• The immunogenicity of chimeric antibodies

  1989cited by this paper
• Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig.

  1989cited by this paper
• Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

  1989cited by this paper
• The brugel package - toward computer-aided-design of macromolecules

  1988cited by this paper
• Reshaping human antibodies: grafting an antilysozyme activity.

  1988cited by this paper
• Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.

  1986cited by this paper
• Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

  1984cited by this paper
• Continuous cultures of fused cells secreting antibody of predefined specificity

  1975cited by this paper

• A novel antibody against GPIbα inhibits platelet function and thrombosis without increasing bleeding.

  2025cites this paper
• Platelet-Type von Willebrand Disease: Complex Pathophysiology and Insights on Novel Therapeutic and Diagnostic Strategies

  2024cites this paper
• Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C

  2023cites this paper
• Blockade of platelet glycoprotein receptor Ib ameliorates blood-brain barrier disruption following ischemic stroke via Epac pathway.

  2021cites this paper
• Quantification of Platelet Contractile Movements during Thrombus Formation

  2018cites this paper
• Inhibitors of Platelet Adhesion to VWF and Collagen

  2017cites this paper
• Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease

  2016cites this paper
• Investigation of the structure of anti-human seminal plasma protein single-chain antibody and its association with linker peptide length

  2015cites this paper
• The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13.

  2015cites this paper
• Soluble expression of human glycoprotein Ibα in Escherichia coli through replacement of the N-terminal capping domain.

  2014cites this paper
• Antibody Humanization Methods for Development of Therapeutic Applications

  2014cites this paper
• Antibody Engineering

  2014cites this paper
• Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ibα and Fc RIIa in immune thrombocytopenia

  2013cites this paper
• Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα

  2013cites this paper
• Platelet-Type von Willebrand Disease: New Insights into the Molecular Pathophysiology of a Unique Platelet Defect

  2013cites this paper
• Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V.

  2012cites this paper
• von Willebrand Factor: An Emerging Target in Stroke Therapy

  2012cites this paper
• Improved platelet survival after cold storage by prevention of glycoprotein Ibα clustering in lipid rafts

  2012cites this paper
• Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis'

  2012cites this paper
• Affinity maturation by semi-rational approaches.

  2012cites this paper
• Humanization and Characterization of an Anti-Human TNF-α Murine Monoclonal Antibody

  2011cites this paper
• Targeting von Willebrand factor and platelet glycoprotein Ib receptor

  2010cites this paper
• Humanization by Resurfacing

  2010cites this paper
• Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke.

  2010cites this paper
• Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro

  2009cites this paper
• Platelet receptors and signaling in the dynamics of thrombus formation

  2009cites this paper
• Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.

  2009cites this paper
• The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons

  2008influential citation
• Affinity maturation of antibodies assisted by in silico modeling

  2008cites this paper
• Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment.

  2008cites this paper
• Humanization of antibodies.

  2008cites this paper
• Paratope and Epitope Mapping of the Antithrombotic Antibody 6B4 in Complex with Platelet Glycoprotein Ibα*

  2007cites this paper
• Anticorps recombinants antithrombotiques

  2006cites this paper
• Survey of the year 2003 commercial optical biosensor literature

  2005cites this paper